Tolerance induction to rofecoxib in a patient with Bartter's syndrome.
Nucera
E
E
Department of Allergology Università Cattolica del Sacro Cuore Policlinico 'A. Gemelli' Largo F. Vito, 1 - 00168 Rome Italy.
Schiavino
D
D
Pollastrini
E
E
Manna
R
R
Di Lillo
M
M
De Lillo
M
M
Buonomo
A
A
Roncallo
C
C
Patriarca
G
G
D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D001477:Bartter Syndrome / Q000188:drug therapy*; D004205:Cromolyn Sodium / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D004890:Erythema / Q000139:chemically induced; D005260:Female; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D017336:Loratadine / Q000627:therapeutic use; D011537:Pruritus / Q000139:chemically induced; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use
D018926:Anti-Allergic Agents; D018927:Anti-Asthmatic Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D017336:Loratadine; D004205:Cromolyn Sodium